Rakovina Therapeutics Announces Extensions and Expansions of Strategic Collaborations to Support AI Research

Expanded Activities Position Rakovina Therapeutics to Capitalize on AI Partnerships with The University of British Columbia and Pharma Inventor Inc.

VANCOUVER, British Columbia, May 08, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company” or “Rakovina Therapeutics”) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies is pleased to announce the expansion of two research collaborations to align with its recently announced collaboration with the Deep Docking AI Drug Discovery Platform.

On March 27, 2024, the Company announced an agreement granting Rakovina Therapeutics exclusive access to the proprietary Deep Docking AI platform for DNA-damage response targets. Using the Deep Docking AI platform, the Company is analyzing billions of molecular structures to evaluate their potential as targeted cancer drugs.

“These partnerships allow us to capitalize on the Deep Docking AI platform while maintaining high standards of research,” said Rakovina Therapeutics Executive Chairman, Jeffrey Bacha. “The most promising lead candidates will be validated using the Company’s established R&D infrastructure and advanced to human clinical trials and pharmaceutical partnerships.”

To support these drug development efforts, the Company has expanded a collaboration with Pharma Inventor Inc., a British Columbia-based chemistry R&D and analytical services company serving pharmaceutical and biotech industries, as well as research institutes and academic research groups across North America. Pharma Inventor has agreed to provide medicinal chemistry support to rapidly synthesize novel lead drug candidates identified by the Deep Docking AI platform for further validation by the Company. Rakovina Therapeutics will own all rights to novel molecules developed through the collaboration.  

The Company has also extended and expanded its collaborative research agreement with the University of British Columbia (UBC). Rakovina Therapeutics’ established lead optimization research infrastructure at the University’s Vancouver Prostate Center will provide rapid validation of novel drug candidates identified through the Deep Docking AI platform.

According to Rakovina Therapeutics President and Chief Scientific Officer, Dr. Mads Daugaard, “We are expanding these important research collaborations to support the company's recently announced collaboration with the Deep Docking AI platform. This ramp-up will position us to capitalize on the opportunity of this collaboration.”